Evidence map›Paper›PMID 25442432›Full record

ReviewThe Canadian journal of cardiology2014

The role of tissue engineering and biomaterials in cardiac regenerative medicine.

Yimu Zhao, Nicole T Feric, Nimalan Thavandiran, Sara S Nunes, Milica Radisic

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Canadian journal of cardiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Cardiac disease mechanobiology: advances using hiPSC-CMs.Frontiers in cardiovascular medicine · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Latest Advances in 3D Bioprinting of Cardiac Tissues.Advanced materials technologies · 2022
    Article
  10. Article
  11. Review
  12. Review
  13. Engineering microenvironment for human cardiac tissue assembly in heart-on-a-chip platform.Matrix biology : journal of the International Society for Matrix Biology · 2020
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yimu ZhaoDepartment of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Ontario, Canada.
Nicole T FericInstitute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada.
Nimalan ThavandiranDepartment of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Ontario, Canada; Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada.
Sara S NunesToronto General Research Institute, University Health Network, Toronto, Ontario, Canada; Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada.
Milica RadisicDepartment of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Ontario, Canada; Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada. Electronic address: m.radisic@utoronto.ca.
University of Toronto · CAUniversity Health Network · CA

Funding

Engineering Vascularized Cardiac MuscleR01HL076485 · NHLBI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Gordana Vunjak-Novakovic · 2005 to 2026
$9.2M
Canadian Institutes of Health Research MOP-126027NHLBI NIH HHS 2R01 HL076485NHLBI NIH HHS R01 HL076485
6 · The paper itself

Abstract

In recent years, the development of 3-dimensional engineered heart tissue (EHT) has made large strides forward because of advances in stem cell biology, materials science, prevascularization strategies, and nanotechnology. As a result, the role of tissue engineering in cardiac regenerative medicine has become multifaceted as new applications become feasible. Cardiac tissue engineering has long been established to have the potential to partially or fully restore cardiac function after cardiac injury. However, EHTs may also serve as surrogate human cardiac tissue for drug-related toxicity screening. Cardiotoxicity remains a major cause of drug withdrawal in the pharmaceutical industry. Unsafe drugs reach the market because preclinical evaluation is insufficient to weed out cardiotoxic drugs in all their forms. Bioengineering methods could provide functional and mature human myocardial tissues, ie, physiologically relevant platforms, for screening the cardiotoxic effects of pharmaceutical agents and facilitate the discovery of new therapeutic agents. Finally, advances in induced pluripotent stem cells have made patient-specific EHTs possible, which opens up the possibility of personalized medicine. Herein, we give an overview of the present state of the art in cardiac tissue engineering, the challenges to the field, and future perspectives.

Indexed as

Biocompatible MaterialsTissue EngineeringAnimalsHeartHeart DiseasesHumansRegenerative MedicineBiocompatible Materials

Identifiers

PMID25442432
PMCPMC4254531
OpenAlexW1996092871

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.